Data Evaluating Heated Lidocaine/Tetracaine Patch for the Treatment of Acute Musculoskeletal Pain to be Presented
Sept. 5, 2013
/PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 announced today that researchers are presenting scientific data related to the heated lidocaine/tetracaine patch (HLT Patch) (70 mg lidocaine/ 70 mg tetracaine) at PAINWeek 2013, to be held
The current marketed version of the HLT Patch, known as the Synera Patch, is FDA approved for use on intact skin to provide local dermal analgesia for superficial venous access and superficial dermatological procedures such as excision, electrodessication and shave biopsy of skin lesions. The Synera Patch is currently marketed in
the United States
by Nuvo's exclusive licensing partner for the current approved indication, Galen US Incorporated (Galen).
The HLT Patch is being developed by Nuvo for the treatment of acute musculoskeletal pain (AMP).
The study in the first poster was conducted to compare 2 different dosing application regimens of the HLT Patch (twice daily and once daily application) and oral naproxen for the treatment of pain associated with lateral epicondylitis (tennis elbow) in a 4-week open-label study that enrolled 52 adult subjects. After 2 weeks of treatment, clinically important reduction in average pain scores (defined as ≥30% reduction from baseline) were experienced by more patients treated with the HLT Patch 4 hr BID (56%) and the HLT Patch 12 hr QD (53%) than by patients treated with oral naproxen (41%). Application site rash or erythema was reported by 50% of patients in the HLT Patch twice daily application group and 18% of patients in the HLT Patch once daily application group. Two patients in the HLT Patch twice daily application group withdrew from the study due to application site adverse events. Two patients in oral naproxen group experienced nausea as an adverse event.